title: Mild cognitive impairment: a systematic review.
abstract: MCI is a nosological entity proposed as an intermediate state between normal aging and dementia. The syndrome can be divided into two broad subtypes: amnestic MCI (aMCI) characterized by reduced memory, and non-amnestic MCI (naMCI) in which other cognitive functions rather than memory are mostly impaired. aMCI seems to represent an early stage of AD, while the outcomes of the naMCI subtypes appear more heterogeneous--including vascular dementia, frontotemporal dementia or dementia with Lewy bodies--but this aspect is still under debate. MCI in fact represents a condition with multiple sources of heterogeneity, including clinical presentation, etiology, and prognosis. To improve classification and prognosis, there is a need for more sensitive instruments specifically developed for MCI as well as for more reliable methods to determine its progression or improvement. Current clinical criteria for MCI should be updated to include restriction in complex ADL; also the diagnostic and prognostic role of behavioral symptoms and motor dysfunctions should be better defined. A multidisciplinary diagnostic approach including biological and neuroimaging techniques may probably represent the best option to predict the conversion from MCI to dementia. In this review we discuss the most recent aspects related to the epidemiological, clinical, neuropathological, neuroimaging, biochemical and therapeutic aspects of MCI, with specific attention to possible markers of conversion to dementia.
authors.affiliation: Section of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Mariani
authors.forename: Roberto
authors.initials: R
authors.lastname: Monastero
authors.forename: Patrizia
authors.initials: P
authors.lastname: Mecocci
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis / Q000453:epidemiology* / Q000378:metabolism; D053327:Apolipoprotein E4 / Q000378:metabolism; D001921:Brain / Q000473:pathology; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology*; D015140:Dementia, Vascular / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008279:Magnetic Resonance Imaging; D008569:Memory Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism; D009483:Neuropsychological Tests; D019275:Radiopharmaceuticals; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D053327:Apolipoprotein E4; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18